Revolutionizing bone defect healing: the power of mesenchymal stem cells as seeds

Y Zhang, M Fan, Y Zhang - Frontiers in Bioengineering and …, 2024 - frontiersin.org
Bone defects can arise from trauma or pathological factors, resulting in compromised bone
integrity and the loss or absence of bone tissue. As we are all aware, repairing bone defects …

Targeted proteomic profiling revealed roles of small gtpases during osteogenic differentiation

YY Yang, R Soh, M Vera-Colón, M Huang… - Analytical …, 2023 - ACS Publications
The small GTPase superfamily of proteins are crucial for numerous cellular processes,
including early development. The roles of these proteins in osteogenic differentiation …

Osteogenesis imperfecta: shifting paradigms in pathophysiology and care in children

S Stasek, F Zaucke, H Hoyer-Kuhn, J Etich… - Journal of Pediatric …, 2024 - degruyter.com
The formation of functional bone requires a delicate interplay between osteogenesis and
osteolysis. Disturbances in this subtle balance result in an increased risk for fractures …

[HTML][HTML] Galunisertib downregulates mutant type I collagen expression and promotes MSCs osteogenesis in pediatric osteogenesis imperfecta

A Infante, N Alcorta-Sevillano, I Macías… - Biomedicine & …, 2024 - Elsevier
Qualitative alterations in type I collagen due to pathogenic variants in the COL1A1 or
COL1A2 genes, result in moderate and severe Osteogenesis Imperfecta (OI), a rare disease …

Exploration of the skeletal phenotype of the Col1a1 +/Mov13 mouse model for haploinsufficient osteogenesis imperfecta type 1

L Claeys, L Zhytnik, LE Wisse, HW van Essen… - Frontiers in …, 2023 - frontiersin.org
Introduction Osteogenesis Imperfecta is a rare genetic connective tissue disorder,
characterized by skeletal dysplasia and fragile bones. Currently only two mouse models …

An exploratory open-label multicentre phase I/II trial evaluating the safety and efficacy of postnatal or prenatal and postnatal administration of allogeneic expanded …

RL Sagar, E Åström, LS Chitty, B Crowe, AL David… - BMJ open, 2024 - bmjopen.bmj.com
Introduction Severe osteogenesis imperfecta (OI) is a debilitating disease with no cure or
sufficiently effective treatment. Mesenchymal stem cells (MSCs) have good safety profile …

[HTML][HTML] Protocol: An exploratory open-label multicentre phase I/II trial evaluating the safety and efficacy of postnatal or prenatal and postnatal administration of …

RL Sagar, E Åström, LS Chitty, B Crowe, AL David… - BMJ Open, 2024 - ncbi.nlm.nih.gov
Introduction Severe osteogenesis imperfecta (OI) is a debilitating disease with no cure or
sufficiently effective treatment. Mesenchymal stem cells (MSCs) have good safety profile …

Murine animal models in osteogenesis imperfecta: The quest for improving the quality of life

N Alcorta-Sevillano, A Infante, I Macías… - International Journal of …, 2022 - mdpi.com
Osteogenesis imperfecta is a rare genetic disorder characterized by bone fragility, due to
alterations in the type I collagen molecule. It is a very heterogeneous disease, both …

ADVANCEMENTS IN OSTEOGENESIS IMPERFECTA TREATMENT: FROM GENETICS TO PERSONALIZED THERAPIES

MEF de Carvalho, VN Binda, VC Destefani… - … CPAQV-Centro de …, 2024 - revista.cpaqv.org
Osteogenesis imperfecta (OI) is a complex genetic disorder characterized by fragile bones
and frequent fractures. It is primarily caused by mutations affecting collagen type I …